• 1.

    Wesson DE, et al. Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial. Lancet 2019; 393:14171427. doi: 10.1016/S0140-6736(18)32562-5

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Tricida, Inc. Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects with Metabolic Acidosis (VALOR-CKD). ClinicalTrials.gov: NCT03710291. https://clinicaltrials.gov/ct2/show/NCT03710291

    • Search Google Scholar
    • Export Citation
  • 3.

    International Society of Nephrology. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3:1150. https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf

    • Search Google Scholar
    • Export Citation

Does Veverimer Hold the Future for Metabolic Acidosis?

  • 1 Katherine Kwon, MD, FASN, is a partner with Lake Michigan Nephrology in St. Joseph, MI.
Restricted access

Veverimer is a novel agent for the treatment of metabolic acidosis in chronic kidney disease (CKD). It is a nonabsorbable polymer that selectively binds hydrochloric acid, leading to excretion of excess acid via the gastrointestinal tract. Veverimer completed a phase 3 clinical trial, demonstrating correction of serum bicarbonate when compared to placebo (1). However, in August 2020, the US Food and Drug Administration (FDA) declined to approve veverimer, requesting additional information on the likelihood of clinical benefit. This prompted manufacturer Tricida to create the VALOR-CKD trial. This ongoing trial will evaluate veverimer’s efficacy against placebo on progression of

Save